Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,365,779 shares of the biopharmaceutical company’s stock after purchasing an additional 195,411 shares during the quarter. Pfizer comprises 0.9% of Mitsubishi UFJ Trust & Banking Corp’s portfolio, making the stock its 15th biggest holding. Mitsubishi UFJ Trust & Banking Corp’s holdings in Pfizer were worth $477,158,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. HL Financial Services LLC increased its stake in Pfizer by 1.1% in the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after acquiring an additional 35,744 shares during the last quarter. Hartford Financial Management Inc. increased its stake in Pfizer by 10.8% in the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 835 shares during the last quarter. Cadence Bank NA increased its stake in Pfizer by 1.4% in the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 1,428 shares during the last quarter. Majedie Asset Management Ltd increased its stake in Pfizer by 7.9% in the 2nd quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock worth $11,320,000 after acquiring an additional 24,531 shares during the last quarter. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its stake in Pfizer by 437.9% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock worth $27,607,000 after acquiring an additional 629,361 shares during the last quarter. 70.06% of the stock is currently owned by institutional investors.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.

Pfizer Inc. (NYSE PFE) opened at $35.19 on Thursday. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $209,760.00, a price-to-earnings ratio of 10.00, a P/E/G ratio of 1.96 and a beta of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the business earned $0.47 EPS. Pfizer’s revenue was up .6% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer declared that its board has initiated a share buyback plan on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.86%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 38.64%.

A number of analysts have issued reports on the company. Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS Group set a $42.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Finally, Berenberg Bank set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $39.45.

TRADEMARK VIOLATION WARNING: “Pfizer Inc. (PFE) Position Increased by Mitsubishi UFJ Trust & Banking Corp” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/15/pfizer-inc-pfe-position-increased-by-mitsubishi-ufj-trust-banking-corp.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.